Despite the early successes at vascular recanalization with percutaneous transluminal angioplasty, vascular restenosis has emerged as a clinical problem of near epidemic proportions. Numerous pharmacologic and mechanical adjuncts have been tried with little success. Over the last few years, there have major advances in our understanding of the biology of the restenotic process. The process is now recognized as a proliferation disorder, and therapies akin to those used in the treatment of malignant diseases are being explored. Endovascular brachytherapy has shown strong potential in controlling this pathologic proliferative process in the laboratory and in early clinical studies. In this review we discuss some of the basic issues involved in vascular restenosis and the current status of endovascular brachytherapy.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/s0360-3016(96)00412-9 | DOI Listing |
JACC Asia
January 2025
Department of Cardiovascular Medicine, Sendai Kousei Hospital, Miyagi, Japan.
J Vasc Access
January 2025
Department of Vascular Surgery, Helios Klinikum Krefeld, Krefeld, Germany.
A 66-year-old transfeminine patient presented to our institution with a central-venous stenosis causing dysfunction of her arteriovenous (AV) graft on her left arm. The patient was treated repeatedly, because of restenosis. Due to complete occlusion of the graft and subclavian vein as well as a liquid tumor located around the stenotic segment of the vein, we resected the left subclavian vein via a trap-door thoracotomy and inserted a PTFE-graft.
View Article and Find Full Text PDFJ Cardiothorac Surg
January 2025
Department of Cardiology, The first Affiliated Hospital of Wannan, Medical College, Wuhu, China.
Background: He's team have recently developed a new Coronary Artery Tree description and Lesion EvaluaTion (CatLet) angiographic scoring system, which is capable of accounting for the variability in coronary anatomy, and risk-stratifying patients with coronary artery disease. Preliminary studies have demonstrated its superiority over the the Synergy between percutaneous coronary intervention with Taxus and Cardiac Surgery (SYNTAX) score with respect to outcome predictions for acute myocardial infarction (AMI) patients. However, there are fewer studies on the prognostic in chronic coronary artery disease(CAD).
View Article and Find Full Text PDFJ Nanobiotechnology
January 2025
Department of Interventional Radiology, Key Laboratory of Interventional Radiology of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450001, China.
Excessive vascularization during tracheal in-stent restenosis (TISR) is a significant but frequently overlooked issue. We developed an anti-inflammatory coupled anti-angiogenic airway stent (PAGL) incorporating anlotinib hydrochloride and silver nanoparticles using advanced electrospinning technology. PAGL exhibited hydrophobic surface properties, exceptional mechanical strength, and appropriate drug-release kinetics.
View Article and Find Full Text PDFGene
January 2025
Department of Pathology and Key Laboratory for Xinjiang Endemic and Ethnic Diseases, Shihezi University School of Medicine/The First Affiliated Hospital, Shihezi University, Shihezi 832002 China; Department of Pathology, Central People's Hospital of Zhanjiang and Zhanjiang Central Hospital, Guangdong Medical University, Zhanjiang 524000 Guangdong, China. Electronic address:
Background: In-stent restenosis (ISR) is one of the most significant complications following percutaneous coronary intervention (PCI) in patients with coronary artery disease (CAD). Ferroptosis is a novel cell death mode characterized by iron overload and lipid peroxidation. However, the role of ferroptosis in vascular smooth muscle cells (VSMCs) regulating neointimal formation during restenosis remains unclear.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!